Summary
- TransMedics has filed to raise $86.25 million in an IPO, although the final figure may be different.
- The company is commercializing an organ transplant care system in the U.S.
- TMDX has grown topline revenue and gross profit from a small base but is burning through cash.
- This idea was discussed in more depth with members of my private investing community, IPO Edge. Start your free trial today »
Quick Take
TransMedics Group (TMDX) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm has developed the Organ Care System [OCS], a portable device that maintains donor organs in a human-like state.
TMDX is growing revenue and gross profit from a small base but needs additional funding for working capital and further development purposes.
